Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
Constantine E Kosmas,1,2 Maria D Bousvarou,3 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,2 Rogers Echavarria Uceta,2 Eliscer Guzman1,2 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2Cardiology Clinic, Cardiology Unlimited, PC, N...
Saved in:
Main Authors: | Kosmas CE (Author), Bousvarou MD (Author), Sourlas A (Author), Papakonstantinou EJ (Author), Peña Genao E (Author), Echavarria Uceta R (Author), Guzman E (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020) -
New and emerging lipid-modifying drugs to lower LDL cholesterol
by: Constantine E Kosmas, et al.
Published: (2021) -
ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
by: Xun Chi, et al.
Published: (2017) -
Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children
by: Fujie Wen, et al.
Published: (2023) -
Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease
by: Sumant Singh Chugh, et al.
Published: (2014)